← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Monoclonal antibodies
seniprutug
L04AG17
Forms & Strengths
- Intravenous infusion solution: concentrations vary by regional approval
Adult Dosing
- Dosing regimen determined by clinical trial protocols or specific regional authorization for targeted autoimmune/inflammatory conditions
- Typically administered via IV infusion under specialist supervision
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
- Not recommended for pediatric use outside of approved clinical trials
Indications
- Investigated and approved in specific jurisdictions for targeted immunomodulatory therapy (e.g., severe inflammatory disorders)
Mechanism of Action
- Monoclonal antibody targeting specific immune pathways
- Modulates immune response by binding to target receptors to reduce inflammation and autoimmune activity
Contraindications
- Hypersensitivity to seniprutug or any excipients in the formulation
- Active severe infections requiring systemic antimicrobial therapy
Adverse Reactions
- Infusion-related reactions (fever, chills, flushing, dyspnea)
- Increased susceptibility to infections
- Elevated liver enzymes
- Headache and fatigue
Drug Interactions
- Live vaccines: Avoid administration during therapy due to risk of disseminated infection
- Immunosuppressants: Potential for additive immunosuppression and increased infection risk
Curated Content: Needs Vetting Before Put to Clinical Use